On February 25, vaccination against coronavirus with the India-produced vaccine Oxford / AstraZeneca (Covishield) started at the vaccination point located at the Kharkiv Regional Children’s Infectious Diseases Clinical Hospital.
Twenty doctors were vaccinated on the first day. Of these, ten are employees of the Kharkiv Regional Clinical Infectious Diseases Hospital, another ten are the emergency medical services staff.
On February 23, the first 500,000 doses of coronavirus vaccination were brought to Ukraine.
On February 24, Kharkiv region received 30,400 doses of vaccine. Dilara Harbuz, 36-year-old, an infectious disease doctor at the Kharkiv Regional Clinical Infectious Diseases Hospital, was the first to be vaccinated. She serves as acting head of the 4th medical diagnostic department, where oxygen-dependent patients are treated.
“I think vaccination is needed. We are in constant contact with patients. We should have permanent immunity because we are most at risk of infection,” considers the doctor.
Out of the 308 healthcare workers of the Kharkiv Regional Clinical Infectious Diseases Hospital, 30 agreed to be vaccinated, that is, every tenth hospital’s medical staff. According to the hospital’s director Pavlo Nartov, the doctors were counting on the German/American Pfizer vaccine. Nartov agreed to be vaccinated with the Indian vaccine, but he does not need it as a matter of priority since he has already had coronavirus.
After inoculation, all those who received vaccines are monitored by doctors for 30 minutes. People with respiratory symptoms, fever, and autoimmune diseases cannot be vaccinated. The vaccination permit is issued by a doctor.
Pavlo Nartov informs that vaccination will start in the districts of Kharkiv region next week.
Reference: The vaccine was registered in Ukraine on February 22. According to the Government portal, it was developed by the University of Oxford and the British-Swedish company AstraZeneca. The Oxford/AstraZeneca emergency vaccine has already been approved by the World Health Organization and has been approved for use by the United Kingdom, the European Union and India. The vaccine, Oxford/AstraZeneca, produced at the Serum Institute (India) has a local (trade) name Covishield.
Text: Natalia Ivanova
Photo: Kharkiv Regional State Administration